The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | How should smoldering multiple myeloma be monitored?
Smoldering multiple myeloma (SMM) is the ideal stage to treat the disease and prevent progression to multiple myeloma (MM). Here, Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, discusses how SMM should be monitored in terms of biology, clinical aspects, imaging and MRD. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
